Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02875548

Title field or adapter rule

{'original_value': 'Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-29T01:00:17.423732+00:00

Published At

2026-10-28T00:00:00+00:00

Record Updated At

2026-10-28

Results Posted At

2026-10-28

Source Retrieved At

2026-10-29T01:00:16.864611+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Diffuse Large B-cell Lymphoma (DLBCL)", "Follicular Lymphoma (FL)", "Synovial Sarcoma", "Epithelioid Sarcoma (ES)", "Mesothelioma", "Advanced Solid Tumors", "Renal Medullary Carcinoma", "Non-Hodgkin Lymphoma (NHL)"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT02875548"

protocolSection.identificationModule.officialTitle

"Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study"

protocolSection.statusModule.overallStatus

"TERMINATED"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

Study condition terms

• Diffuse Large B-cell Lymphoma (DLBCL) (protocolSection.conditionsModule.conditions)
• Follicular Lymphoma (FL) (protocolSection.conditionsModule.conditions)
• Synovial Sarcoma (protocolSection.conditionsModule.conditions)
• Epithelioid Sarcoma (ES) (protocolSection.conditionsModule.conditions)
• Mesothelioma (protocolSection.conditionsModule.conditions)
• Advanced Solid Tumors (protocolSection.conditionsModule.conditions)
• Renal Medullary Carcinoma (protocolSection.conditionsModule.conditions)
• Non-Hodgkin Lymphoma (NHL) (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Open-label Tazemetostat'], 'description': 'Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of enhancer of Zeste homolog 2 (EZH2), a histone-lysine N-methyltransferase enzyme.', 'name': 'Tazemetostat', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Tazemetostat (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.